Switch theme
Sign up to access all valuation multiples
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
2018
107
LTM Revenue $0.7M
LTM EBITDA n/a
-$136M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Neurogene has a last 12-month revenue of $0.7M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Neurogene achieved revenue of $0.9M and an EBITDA of -$71.9M.
Neurogene expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Neurogene valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | $0.9M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$33.0M | -$71.9M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -7771% | XXX | XXX | XXX |
| Net Profit | -$55.2M | -$36.3M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -3926% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Neurogene's stock price is $11.
Neurogene has current market cap of $163M, and EV of -$136M.
See Neurogene trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$136M | $163M | XXX | XXX | XXX | XXX | $-4.35 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Neurogene has market cap of $163M and EV of -$136M.
Neurogene's trades at -205.8x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Neurogene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Neurogene and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$136M | XXX | XXX | XXX |
| EV/Revenue | -146.6x | XXX | XXX | XXX |
| EV/EBITDA | 1.9x | XXX | XXX | XXX |
| P/E | -2.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 1.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpNeurogene's NTM/LTM revenue growth is -100%
Neurogene's revenue per employee for the last fiscal year averaged $9K, while opex per employee averaged $0.8M for the same period.
Over next 12 months, Neurogene's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Neurogene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Neurogene and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | Infinity% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -7771% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 118% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $9K | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.8M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2445% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 6586% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 9030% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Neurogene acquired XXX companies to date.
Last acquisition by Neurogene was XXXXXXXX, XXXXX XXXXX XXXXXX . Neurogene acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Neurogene founded? | Neurogene was founded in 2018. |
| Where is Neurogene headquartered? | Neurogene is headquartered in United States of America. |
| How many employees does Neurogene have? | As of today, Neurogene has 107 employees. |
| Who is the CEO of Neurogene? | Neurogene's CEO is Dr. Rachel McMinn, PhD. |
| Is Neurogene publicy listed? | Yes, Neurogene is a public company listed on NAS. |
| What is the stock symbol of Neurogene? | Neurogene trades under NGNE ticker. |
| When did Neurogene go public? | Neurogene went public in 2023. |
| Who are competitors of Neurogene? | Similar companies to Neurogene include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Neurogene? | Neurogene's current market cap is $163M |
| What is the current revenue of Neurogene? | Neurogene's last 12-month revenue is $0.7M. |
| What is the current EV/Revenue multiple of Neurogene? | Current revenue multiple of Neurogene is -205.8x. |
| Is Neurogene profitable? | Yes, Neurogene is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
